Stay updated on Viatris Press Releases

Sign up to get notified when there's something new on the Viatris Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Viatris Press Releases page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    Viatris has appointed Andrew Enrietti as the Chief Administrative and Transformation Officer, marking a significant leadership change. The previous announcement regarding Viatris's participation in upcoming investor conferences has been removed.
    Difference
    15%
    Check dated 2025-08-24T07:26:04.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The web page now includes an announcement regarding the approval of the first generic Iron Sucrose Injection by Viatris in the U.S., while a previous report on Viatris's first quarter results and outlook for 2025 has been removed.
    Difference
    19%
    Check dated 2025-08-17T00:57:57.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    Viatris has announced the appointment of David Simmons to its Board of Directors and reported its second quarter 2025 results while reiterating its financial guidance for the year. Notably, several previous announcements regarding positive study results for new products have been removed.
    Difference
    100%
    Check dated 2025-08-09T20:08:23.000Z thumbnail image
  7. Check
    47 days ago
    Change Detected
    Summary
    The page now includes an announcement about Viatris presenting data on a new medication at the PAINWeek 2025 Conference, while a previous announcement regarding board appointments has been removed.
    Difference
    21%
    Check dated 2025-08-02T15:34:58.000Z thumbnail image
  8. Check
    61 days ago
    Change Detected
    Summary
    The page has been updated to include a new announcement regarding Viatris' Phase 3 study of MR-139 for Blepharitis, while a previous announcement about Viatris' presentation at a healthcare conference has been removed.
    Difference
    16%
    Check dated 2025-07-19T11:21:41.000Z thumbnail image
  9. Check
    83 days ago
    Change Detected
    Summary
    The webpage has been updated to include the announcement of positive results from a pivotal trial for MR-141 in presbyopia, while the previous filing for EFFEXOR® in Japan has been removed.
    Difference
    26%
    Check dated 2025-06-27T21:38:33.000Z thumbnail image

Stay in the know with updates to Viatris Press Releases

Enter your email address, and we'll notify you when there's something new on the Viatris Press Releases page.